Physician profile
Seth Compton
NPI 1043449598
$22,395.55
in general payments reported to CMS, 2019-2025
35 companies · $3,290 in 2025
The $3,290 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,460 · 2020: $2,270 · 2021: $3,302 · 2022: $3,048 · 2023: $3,335 · 2024: $3,690 · 2025: $3,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,146.43 |
| Education | $168.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,710.51 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $4,736.55 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,527.36 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,472.97 | 2019-2025 | |
| Ucb, INC. | $1,250.59 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,168.26 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,167.39 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $822.57 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $722.09 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $626.18 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $551.40 | 2019-2025 | Orencia, Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.39 | 2019-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $357.50 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $266.41 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $245.63 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $222.18 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $199.14 | 2019-2025 | Gazyva |
| Fresenius Kabi USA, LLC | $149.77 | 2023-2025 | Idacio, Tyenne |
| Genzyme Corporation | $142.96 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $131.12 | 2022-2025 | Strensiq |
| Radius Health, INC. | $114.00 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Organon LLC | $42.82 | 2024-2025 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $29.12 | 2019 | |
| Medexus Pharma, INC. | $25.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2019 | |
| Sandoz INC. | $21.67 | 2024 | Hyrimoz |
| Invivyd INC | $20.49 | 2025 | Pemgarda |
| Assertio Therapeutics, INC. | $17.61 | 2019 | |
| Novo Nordisk INC | $17.10 | 2022 | |
| Sobi, INC | $17.03 | 2020 | |
| Celgene Corporation | $15.79 | 2019 | |
| Mylan Institutional INC. | $15.13 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.64 | 2024 | Keveyis |
| Hikma Pharmaceuticals USA | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.